| Bias | Author's judgement | Support for judgement |
| Confounding |
Moderate |
Comment: The confounders of interest (age, sex, comorbidities, severity, insurance) were controlled for in the propensity score model |
| Selection of participants into the study |
Low |
Comment: Forty-five adult patients were identified as eligible for COVID-19 convalescent plasma transfusion under the criteria established for the FDA single patient emergency investigational new drug (eIND) process |
| Intervention classification |
Low |
A medical data team reviewed charts of the control patients to determine outcomes at 1, 7, and 14 days. The data team was not informed of the recipient to whom each control patient was matched. Because control patients were matched to plasma recipients by length of stay prior to transfusion, “day 0” was defined as the day of transfusion for the plasma recipients and as the corresponding day in the hospitalization course of the control patients. |
| Deviation from intended intervention |
Low |
* |
| Missing data |
Low |
No missing data |
| Measurements of outcomes |
Low |
A medical data team reviewed charts of the control patients to determine outcomes at 1, 7, and 14 days. The data team was not informed of the recipient to whom each control patient was matched. Because control patients were matched to plasma recipients by length of stay prior to transfusion, “day 0” was defined as the day of transfusion for the plasma recipients and as the corresponding day in the hospitalization course of the control patients. |
| Selection of the reported results |
Moderate |
Comment: No protocol available, the mortality analysis was presented only subgroup |